Radiation for limited, progressing prostate cancer on abiraterone
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether a very focused type of radiation (SABR) can control a small number of prostate cancer spots that are starting to grow while you’re already on abiraterone. It may help by treating only the areas that are progressing, while other areas remain controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to carry out daily activities normally (ECOG 0–1).
- Your prostate cancer has been confirmed by biopsy/pathology as prostate adenocarcinoma.
- Your cancer is metastatic and has become resistant to castration treatments (castration-resistant).
- You are currently being treated with abiraterone.
- Scans show only a small number of spots are progressing (oligoprogression), and the total number is limited (about 5 or fewer).
- All cancer spots being treated can safely receive SABR (very focused radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precise, high-dose radiation technique (SABR) for people whose cancer has started to grow again in only a few spots despite ongoing medication. The goal is to control those new growths while continuing your current treatment.
This trial tests whether giving focused radiation to limited areas of cancer growth (up to 3 spots) can help control the disease in men with castration-resistant prostate cancer. You may be eligible if your cancer is growing slowly and you are already on hormone therapy.
This study is testing whether using focused radiation beams (SBRT) right away or later, along with hormone therapy, can help control prostate cancer that has returned in a few spots outside the pelvis. The goal is to find the best timing for combining radiation and hormone treatment.
This trial tests whether two “ablative” (high-dose, focused) radiation treatments can work well for men with favorable-risk prostate cancer. It looks at whether the treatments are practical and safe, especially for urinary side effects.
This study tests a precise radiation technique called SABR to treat cancer that has spread to a few spots. It aims to see if this approach can help control the cancer better than usual treatment, especially for lung, prostate, colorectal, or other solid tumors with limited spread.
This trial tests whether targeted radiation (SBRT) to a few sites of cancer spread can help men whose prostate cancer has stopped responding to hormone therapy but has not spread to many places. You may benefit if you have a limited number of growing spots outside the brain or spine.
Hear when a new Oligoprogressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.